{"nct_id":"NCT01578499","title":"A Phase 3 Trial of Brentuximab Vedotin(SGN-35) Versus Physician's Choice (Methotrexate or Bexarotene) in Participants With CD30-Positive Cutaneous T-Cell Lymphoma (ALCANZA Study)","status":"COMPLETED","status_verified_date":"2020-12","start_date":"2012-06-11","start_date_type":"ACTUAL","primary_completion_date":"2016-05-31","primary_completion_date_type":"ACTUAL","completion_date":"2018-07-06","completion_date_type":"ACTUAL","phases":["PHASE3"],"tickers":["TAK"]}